NCT02727790

Brief Summary

The epidemic nature of type 2 diabetes mellitus, along with the downsides of current treatments, has raised the need for therapeutic alternatives. The aim of this study is to evaluate safety, tolerability, and the glucose-lowering effect of noninvasive peripheral electrical stimulation (PES) as an alternative treatment for diabetes.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
12

participants targeted

Target at below P25 for not_applicable type-2-diabetes-mellitus

Timeline
Completed

Started Jul 2014

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2014

Completed
1.7 years until next milestone

First Submitted

Initial submission to the registry

February 28, 2016

Completed
1 month until next milestone

First Posted

Study publicly available on registry

April 5, 2016

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2016

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2016

Completed
Last Updated

June 7, 2016

Status Verified

March 1, 2016

Enrollment Period

1.9 years

First QC Date

February 28, 2016

Last Update Submit

June 6, 2016

Conditions

Outcome Measures

Primary Outcomes (1)

  • Number of participants with hypoglycemia, and/ or adverse events that are related to treatment

    Baseline through 2 months

Secondary Outcomes (2)

  • Incidence of minor side effects related to treatment

    Baseline through 2 months

  • Changes in mean interstitial glucose levels measured by CGM

    Baseline, 1, 2, 5, and 6 weeks

Study Arms (2)

PES Treatment

EXPERIMENTAL

Eligible patients will receive daily 5 min PES treatment for two weeks. Interstitial glucose will be monitored throughout the study using a FreeStyle Navigator (Abbott Diabetes Care, Alameda, CA) continuous glucose monitor (CGM) System

Device: Stimulator

Control

NO INTERVENTION

Interstitial glucose will be monitored throughout the study using a FreeStyle Navigator (Abbott Diabetes Care, Alameda, CA) CGM System

Interventions

Also known as: BEAC Biomedical Intellistim BE-28TC
PES Treatment

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients diagnosed with type II diabetes, for at least one year prior to randomization
  • Body mass index BMI \< 35 Kg/m2
  • Stable glucose lowering drugs regimen for at least one month prior to randomization
  • Capable of giving informed consent

You may not qualify if:

  • Pregnancy, or nursing
  • \< HbA1c \< 6
  • Permanent pacemakers
  • Metal prosthesis
  • Resting blood pressure \> 160/ 100 mmHg
  • Skin disease
  • Treatment with steroids or beta-blockers treatment with psychiatric medications

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Assaf-Harofeh Medical Center

Ẕerifin, 70300, Israel

Location

Related Publications (1)

  • Catalogna M, Doenyas-Barak K, Sagi R, Abu-Hamad R, Nevo U, Ben-Jacob E, Efrati S. Effect of Peripheral Electrical Stimulation (PES) on Nocturnal Blood Glucose in Type 2 Diabetes: A Randomized Crossover Pilot Study. PLoS One. 2016 Dec 20;11(12):e0168805. doi: 10.1371/journal.pone.0168805. eCollection 2016.

MeSH Terms

Conditions

Diabetes Mellitus, Type 2

Interventions

Tissue Therapy, Historical

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System Diseases

Intervention Hierarchy (Ancestors)

OrganotherapyBiological TherapyTherapeuticsComplementary Therapies

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
OTHER GOV
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 28, 2016

First Posted

April 5, 2016

Study Start

July 1, 2014

Primary Completion

June 1, 2016

Study Completion

June 1, 2016

Last Updated

June 7, 2016

Record last verified: 2016-03

Locations